<?xml version="1.0" encoding="UTF-8"?><add><doc><field name="id">0009137</field><field name="title">MAY UPGRADE UPJOHN [UPJ] DEBT RATINGS</field><field name="place">NEW YORK</field><field name="date">April 3</field><field name="content">- Moody's Investors Service Inc said it may upgrade the ratings on Upjohn Co's 400 mln dlrs of debt.     The agency said it will study the effect new products may have on Upjohn's earnings potential. Moody's will also assess the effects that growth and a broader diversification of pharmaceutical cash flow will have on operating performance.     Moody's noted that pharmaceuticals and other health-care markets are characterized by a greater stability of cash flow.     Upjohn currently carries Aa-3 senior unsecured long-term debt and industrial revenue bonds. The company's Prime-1 commercial paper is not under review. </field></doc></add>